Severe Ocular Irritation and Corneal Deposits Associated with Capecitabine Use
- 7 September 2000
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 343 (10) , 740-741
- https://doi.org/10.1056/nejm200009073431015
Abstract
Capecitabine (Xeloda, Roche Laboratories) is an orally administered fluoropyrimidine carbamate used for the treatment of metastatic breast cancer and colon cancer.1-4 We describe two patients in whom marked ocular irritation, decreased vision, and corneal deposits developed during chemotherapy with capecitabine.Keywords
This publication has 2 references indexed in Scilit:
- Xeloda® in the Treatment of Metastatic Breast CancerOncology, 1999
- CapecitabineDrugs, 1999